Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma

Study Status

Open to Enrollment

Study Description

Monoclonal antibodies can fight lymphoma by binding to proteins expressed on lymphoma cells and either directly killing or inducing the immune system to kill the tumor cells.   With radioimmunotherapy, the antibody is labeled with a radioactive molecule, allowing directed delivery of radiation to the lymphoma.  Radioimmunotherapy is effective in follicular lymphoma, but immune reactions against the radiolabeled antibody have limited the utility of this approach.  In this study, we are evaluating the combination of an unlabeled antibody to one lymphoma-associated protein (CD20) with a radio-labeled antibody to a different lymphoma-associated protein (CD22), in hopes of improving responses.  The antibodies are modified to minimize immune responses, and both antibodies will be given in repeated doses in order to increase the total amount of drug administered while limiting side effects.

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Follicular Lymphoma


Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with Follicular Lymphoma
  • No more than 2 prior systemic treatments for non-Hodgkin's Lymphoma
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page